{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:36:17Z","timestamp":1761489377120},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.lungcan.2014.05.006","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T20:46:16Z","timestamp":1400100376000},"page":"251-257","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of phase 1 trials in malignant pleural mesothelioma: Description of a series of patients at a single institution"],"prefix":"10.1016","volume":"85","author":[{"given":"J.","family":"Raphael","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Le Teuff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Massard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bahleda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Margery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"May (13)","key":"10.1016\/j.lungcan.2014.05.006_bib0005","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"June (6)","key":"10.1016\/j.lungcan.2014.05.006_bib0010","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/oem.2005.023200","article-title":"The French National Mesothelioma Surveillance Program","volume":"63","author":"Goldberg","year":"2006","journal-title":"Occup Environ Med"},{"issue":"June (3)","key":"10.1016\/j.lungcan.2014.05.006_bib0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2486\/indhealth.45.379","article-title":"Malignant mesothelioma: global incidence and relationship with asbestos","volume":"45","author":"Bianchi","year":"2007","journal-title":"Ind Health"},{"issue":"July (7)","key":"10.1016\/j.lungcan.2014.05.006_bib0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1024\/0040-5930\/a000306","article-title":"Malignant pleural mesothelioma","volume":"69","author":"Opitz","year":"2012","journal-title":"Ther Umsch"},{"issue":"March (10)","key":"10.1016\/j.lungcan.2014.05.006_bib0025","first-page":"481","article-title":"Malignant pleural mesothelioma","volume":"137","author":"Ploenes","year":"2012","journal-title":"Dtsch Med Wochenschr"},{"issue":"April (12)","key":"10.1016\/j.lungcan.2014.05.006_bib0030","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J Clin Oncol"},{"issue":"August (8)","key":"10.1016\/j.lungcan.2014.05.006_bib0035","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"issue":"July (14)","key":"10.1016\/j.lungcan.2014.05.006_bib0040","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.lungcan.2014.05.006_bib0045","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"Van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"issue":"March (3)","key":"10.1016\/j.lungcan.2014.05.006_bib0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/fon.12.14","article-title":"Systemic treatment of malignant pleural mesothelioma","volume":"8","author":"Grosso","year":"2012","journal-title":"Future Oncol"},{"issue":"February (1)","key":"10.1016\/j.lungcan.2014.05.006_bib0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2009.09.003","article-title":"Second-line treatment for malignant pleural mesothelioma","volume":"36","author":"Ceresoli","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"March 14","key":"10.1016\/j.lungcan.2014.05.006_bib0060","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2014.05.006_bib0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000339259","article-title":"Malignant pleural mesothelioma: from the bench to the bedside","volume":"83","author":"Astoul","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0070","series-title":"AJCC cancer staging manual","author":"Edge","year":"2010"},{"issue":"1","key":"10.1016\/j.lungcan.2014.05.006_bib0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleuralmesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0080","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","author":"Zucali","year":"2013","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2014.05.006_bib0085","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","article-title":"A phase II study of gemcitabine in patients with malignantpleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"85","author":"Van Meerbeeck","year":"1999","journal-title":"Cancer"},{"issue":"2\u20133","key":"10.1016\/j.lungcan.2014.05.006_bib0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0169-5002(00)00166-5","article-title":"Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B","volume":"31","author":"Kindler","year":"2001","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2014.05.006_bib0095","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"issue":"March (3)","key":"10.1016\/j.lungcan.2014.05.006_bib0100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"issue":"April (1)","key":"10.1016\/j.lungcan.2014.05.006_bib0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2014.05.006_bib0110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000087376","article-title":"Serum PDGF-AB in pleural mesothelioma","volume":"26","author":"Filiberti","year":"2005","journal-title":"Tumour Biol"},{"issue":"5","key":"10.1016\/j.lungcan.2014.05.006_bib0115","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0046-8177(98)90066-1","article-title":"Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders","volume":"29","author":"Arber","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-011-1655-3","article-title":"Review on clinical trials of targeted treatments in malignant mesothelioma","volume":"68","author":"Jakobsen","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinicopathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","article-title":"Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial","volume":"50","author":"Mathy","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0135","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-006-0243-4","article-title":"Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma","volume":"59","author":"Porta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0140","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0145","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0150","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.hoc.2005.09.008","article-title":"Antiangiogenic therapies for mesothelioma","volume":"19","author":"Dowell","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"issue":"18","key":"10.1016\/j.lungcan.2014.05.006_bib0155","first-page":"70","article-title":"Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107)","volume":"24","author":"Jahan","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"18S","key":"10.1016\/j.lungcan.2014.05.006_bib0160","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.1200\/jco.2007.25.18_suppl.7707","article-title":"Sorafenib in malignant mesothelioma: a phase II trial of the Cancer and Leukemia Group B (CALGB 30307) (abstract)","volume":"25","author":"J\u00e4nne","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0165","first-page":"63","article-title":"Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM) (abstract)","volume":"26","author":"Nowak","year":"2008","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"May (6)","key":"10.1016\/j.lungcan.2014.05.006_bib0170","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"July (20)","key":"10.1016\/j.lungcan.2014.05.006_bib0175","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multi-center, double blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"issue":"August (3)","key":"10.1016\/j.lungcan.2014.05.006_bib0180","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2010.28.15_suppl.7020","article-title":"IFCT-GFPC-0701 MAPS trial, a multicentre randomized phase II\/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma","volume":"28","author":"Zalcman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.lungcan.2014.05.006_bib0190","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1158\/1535-7163.MCT-07-0052","article-title":"Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion","volume":"6","author":"Tsao","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.lungcan.2014.05.006_bib0195","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLC.2006.n.003","article-title":"Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid","volume":"7","author":"Krug","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0200","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-07-0536","article-title":"Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma","volume":"13","author":"Sartore-Bianchi","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.lungcan.2014.05.006_bib0205","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00280-007-0500-1","article-title":"Preclinical studies of the proteasome inhibitor Bortezomib in malignant pleural mesothelioma","volume":"61","author":"Gordon","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s13665-012-0010-4","article-title":"Emerging therapies for malignant pleural mesothelioma","volume":"1","author":"Josine","year":"2012","journal-title":"Curr Respir Care Rep"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0215","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"issue":"September (Supplement 2)","key":"10.1016\/j.lungcan.2014.05.006_bib0220","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0959-8049(11)70098-3","article-title":"VANTAGE 014: vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial","volume":"47","author":"Krug","year":"2011","journal-title":"Eur J Cancer"},{"issue":"January (1)","key":"10.1016\/j.lungcan.2014.05.006_bib0225","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","article-title":"Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials","volume":"20","author":"Fert\u00e9","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"October (10)","key":"10.1016\/j.lungcan.2014.05.006_bib0230","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"issue":"July (2)","key":"10.1016\/j.lungcan.2014.05.006_bib0235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"issue":"September (12)","key":"10.1016\/j.lungcan.2014.05.006_bib0240","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N Engl J Med"},{"issue":"February (2)","key":"10.1016\/j.lungcan.2014.05.006_bib0245","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"issue":"May (Suppl. 5)","key":"10.1016\/j.lungcan.2014.05.006_bib0250","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdq173","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Stahel","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2014.05.006_bib0255","series-title":"AACR annual meeting","article-title":"Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. Abstract CT 240","author":"Ferte","year":"2014"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214002153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214002153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T12:12:07Z","timestamp":1597839127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500214002153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0169500214002153"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.05.006","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of phase 1 trials in malignant pleural mesothelioma: Description of a series of patients at a single institution","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}